INSM Live signals | Maximize Profits with Getagraph.com

BUY 73443 min ago

@ $28.97

Issued: 28 Feb 2024 @ 09:30

Return: -15.74%

Previous signal: Feb 27 - 15:07

Previous signal: Sell

Return: -1.16 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 10:33):

Stats
Today's Volume	581 878
Average Volume	1.60M
Market Cap	3.62B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-1.210 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.57
ATR14	$0.0590 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Lewis William	Buy	50 000	Common Stock
2024-02-28	Lewis William	Buy	50 000	Stock Option (right to buy)
2024-02-28	Sharoky Melvin Md	Sell	3 600	Common Stock
2024-02-28	Sharoky Melvin Md	Buy	1 200	Common Stock
2024-02-28	Sharoky Melvin Md	Buy	1 200	Common Stock

INSIDER POWER
36.56
Last 100 transactions
Buy: 1 120 971 \| Sell: 555 042

Volume Correlation

Long: 0.11 (neutral)

Short: -0.74 (moderate negative)

Signal:(48.504) Neutral

Insmed Inc Correlation

10 Most Positive Correlations
ONBPP	0.872
CNDT	0.868
ANNX	0.868
PRAX	0.866
NETE	0.854
ICCC	0.853
WAFDP	0.851
DCOMP	0.847
SRAX	0.846
TTEC	0.846

10 Most Negative Correlations
RMRM	-0.836
PAIC	-0.832
SVAC	-0.829
EPZM	-0.82
SPRT	-0.816
UNCY	-0.816
TYHT	-0.811
CNST	-0.806
CNCE	-0.804
DRNA	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Insmed Inc Correlation - Currency/Commodity

-0.90
( strong negative )

-0.80
( moderate negative )

0.00
( neutral )

-0.85
( strong negative )

-0.76
( moderate negative )

-0.37
( neutral )

Insmed Inc Financials

Annual	2023
Revenue:	$305.21M
Gross Profit:	$239.64M (78.52 %)
EPS:	$-5.34

Q4	2023
Revenue:	$83.69M
Gross Profit:	$65.25M (77.96 %)
EPS:	$-1.280

Q3	2023
Revenue:	$79.07M
Gross Profit:	$62.37M (78.87 %)
EPS:	$-1.110

Q2	2023
Revenue:	$77.23M
Gross Profit:	$60.64M (78.51 %)
EPS:	$-1.780

Financial Reports:

No articles found.

Insmed Inc

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.